Login · Contact

Akorn Pharmaceuticals

Akorn Investor Relations
2016 Press Releases
Webcast ImageWebcast
Akorn, Inc. at 35th Annual J.P. Morgan Healthcare Conference (Replay)
01/09/17 at 4:30 p.m. PT
Akorn, Inc. at 35th Annual J.P. Morgan Healthcare Conference
Monday, January 9, 2017 4:30 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast
Q4 2016 Akorn, Inc. Earnings Conference Call (Replay)
03/01/17 at 9:00 a.m. CT
Q4 2016 Akorn, Inc. Earnings Conference Call
Wednesday, March 1, 2017 9:00 a.m. CT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016
DateTitle 
12/21/16Akorn to Present at 35th Annual J.P Morgan Healthcare Conference
LAKE FOREST, Ill., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn’s CEO, Raj Rai, will present at the 35th Annual J.P. Morgan Healthcare Conference. Event: J.P. Morgan Healthcare Conference Date: January 9, 2017 Time: 4:30 PM PT Location: San Francisco, California The presentation will be webcast live and available on the “Events & Presentations” page in the Investor Relations section of th... 
Printer Friendly Version
12/12/16Akorn Announces Completion of FDA Re-inspection of Decatur Facility
LAKE FOREST, Ill., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) conducted a re-inspection of its Decatur, Illinois manufacturing facility from December 5, 2016 to December 9, 2016, with no Form 483 observations.   The re-inspection was conducted to verify the implementation and effectiveness of Akorn’s responses to the observations from the June 2016 FDA inspection. ... 
Printer Friendly Version
11/29/16Akorn Launches Ibuprofen Oral Suspension
LAKE FOREST, Ill., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has launched the prescription version of Ibuprofen 100mg/5mL oral suspension in 118mL and 473mL bottles as well as 5mL unit dose cups. About Ibuprofen 100mg/5mL Oral Suspension Ibuprofen Oral Suspension, USP is a sucrose-sweetened, orange-colored, berry-flavored suspension containing 100 mg of ibuprofen in 5 mL (20 mg/mL). In Pediatric Patients,... 
Printer Friendly Version
11/28/16Akorn Invalidates Durezol® Patent Via Inter Partes Review Proceeding
LAKE FOREST, Ill., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that on November 22, 2016, the Patent Trial and Appeal Board (PTAB) ruled in favor of Akorn in its inter partes review (IPR) proceeding and found all the claims of the 6,114,319 patent (“ ‘319 patent”) related to the Durezol® formulation to be obvious. The ‘319 patent, directed to emulsions of difluprednate, is owned by Senju Pharmaceutical Co., Ltd. and M... 
Printer Friendly Version
11/16/16Akorn to Present at Piper Jaffray 28th Annual Healthcare Conference
LAKE FOREST, Ill., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn’s Chief Financial Officer, Duane Portwood, will present at the Piper Jaffray 28th Annual Healthcare Conference. Event: Piper Jaffray 28th Annual Healthcare Conference Date: November 29, 2016 Time: 8:30 a.m. ET Location: Lotte New York Palace, New York, NY The presentation will be webcast live and available on the “Events & Pre... 
Printer Friendly Version
11/03/16Akorn Provides Third Quarter 2016 Results
- Q3 2016 Revenue Increase of 11% to $284 million - - Q3 2016 GAAP EPS of $0.38; Adjusted Q3 2016 EPS of $0.56 - - Updates 2016 Revenue, EPS and Adjusted EBITDA Guidance - - Repurchased $25 Million of Shares - - Conference Call and Webcast to Be Held November 3, 2016 at 10:00 a.m. EDT - LAKE FOREST, Ill., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the third quarter of 2016. A... 
Printer Friendly Version
10/13/16Akorn Announces Third Quarter 2016 Earnings Release and Conference Call Information
LAKE FOREST, Ill., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, November 3, 2016 outlining the third quarter 2016 results. In addition, the Company will host a conference call at 10:00 am EDT on the same day to discuss its third quarter 2016 financial results. The dial-in number to access the call is (844) 249-9382 in the U.S. and +1 (270) 823-1530 for inte... 
Printer Friendly Version
08/25/16Akorn Relaunches Ofloxacin Otic Solution
LAKE FOREST, Ill., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has relaunched Ofloxacin Otic Solution 0.3%, a sterile aqueous anti-infective solution for otic use. About Ofloxacin Otic Solution Ofloxacin Otic Solution is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediat... 
Printer Friendly Version
08/24/16Akorn to Present at Morgan Stanley Global Healthcare Conference
LAKE FOREST, Ill., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn’s CEO, Raj Rai, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference. Event: Morgan Stanley Healthcare Conference Date: September 13, 2016 Time: 12:20 p.m. ET Location: New York, NY The fireside chat will be webcast live and available on the “Events & Presentations” page in the Investor Relati... 
Printer Friendly Version
08/18/16Akorn Appoints Robert Monahan as Senior Vice President of Corporate Development
LAKE FOREST, Ill., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Rob Monahan has recently joined Akorn as Senior Vice President of Corporate Development. Mr. Monahan joins Akorn from Walgreens Boots Alliance, Inc. (formerly Walgreen Co.), where he was a corporate development professional focused on Mergers & Acquisitions since 2009, most recently as Vice President of Mergers & Acquisitions.  At W... 
Printer Friendly Version
08/04/16Akorn Provides Second Quarter 2016 Results
- Q2 2016 Revenue Increase of 27% to $281 Million - - Q2 2016 GAAP EPS Increase of 85% to $0.50; Adjusted Q2 2016 EPS Increase of 41% to $0.58 - - Updates 2016 Revenue and EPS Guidance - - Board of Directors Authorizes $200 Million Stock Repurchase Program - - Conference Call and Webcast to Be Held August 4, 2016 at 10:00 a.m. EDT - LAKE FOREST, Ill., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced its fina... 
Printer Friendly Version
07/21/16Akorn Announces Second Quarter 2016 Earnings Release and Conference Call Information
LAKE FOREST, Ill., July 21, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Thursday, August 4, 2016 outlining the second quarter 2016 results. In addition, the Company will host a conference call at 10:00 am EDT on the same day to discuss its second quarter 2016 financial results. The dial-in number to access the call is (844) 249-9382 in the U.S. and +1 (270) 823-1530 for inte... 
Printer Friendly Version
06/02/16Akorn Updates Form S-8 Status by Filing Form 10-Q’s for First, Second and Third Quarters of 2015
LAKE FOREST, Ill., June 02, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has filed quarterly reports on Forms 10-Q with the Securities and Exchange Commission (SEC) for the quarters ended March 31, 2015, June 30, 2015 and September 30, 2015.  The quarterly financial results that are included in the individual Forms 10-Q were previously filed by the Company in its comprehensive Form 10-K for the fiscal year 2015 ... 
Printer Friendly Version
05/31/16Akorn to Present at Two Upcoming Investor Conferences
LAKE FOREST, Ill., May 31, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that management will be presenting at the Jefferies 2016 Healthcare Conference and William Blair 36th Annual Growth Stock Conference in June. Jefferies 2016 Global Healthcare Conference Date: Thursday, June 9, 2016 Time: 9:00 a.m. ET Location: New York, NY William Blair 36th Annual Growth Stock Conference Date: Wednesday, June 15, 2016 Time... 
Printer Friendly Version
05/16/16Akorn Provides First Quarter 2016 Results
- Q1 2016 GAAP Revenue of $268 million - - GAAP EPS of $0.34; Adjusted Q1 2016 EPS of $0.54 - - Conference Call and Webcast to Be Held May 17, 2016 at 10:00 a.m. EDT - LAKE FOREST, Ill., May 16, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today provided first quarter 2016 financial results. Akorn also provided material updates on several other important business items. Q1 2016 Operating Highlights: Achieved first quarter cons... 
Printer Friendly Version
05/10/16Akorn Completes 2014 Financial Statement Restatement and Reports Audited 2015 and Restated 2014 Results
- Sets Date for 2016 Annual Meeting - Affirms 2016 Net Revenue and Earnings per Share Guidance LAKE FOREST, Ill., May 10, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has filed its Annual Report on Form 10-K for the fiscal year December 31, 2015 (“Form 10-K”).  The Company is now up to date on filing its periodic reports with the Securities and Exchange Commission (the “SEC”).  The Company also announced p... 
Printer Friendly Version
05/06/16Akorn Outlines Timeline for 2015 Form 10-K Filing, First Quarter 2016 Form 10-Q Filing and Investor Conference Calls
LAKE FOREST, Ill., May 06, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced the target dates for upcoming filings and press releases.  On Monday, May 9, 2016 after market close, the Company plans to file a comprehensive Annual Report on Form 10-K for the year ended December 31, 2015.  The comprehensive Form 10-K will contain the consolidated financial statements for the year ended December 31, 2015 and consolidated restated... 
Printer Friendly Version
03/22/16Akorn Provides Preliminary Unaudited Full Year 2015 Financial Results and Issues 2016 Financial Guidance
- Preliminary 2015 GAAP Revenue of $985 Million - - Preliminary 2015 GAAP EPS of $1.14; Preliminary Adjusted 2015 EPS of $1.93 - - GAAP Revenue of $1.06 - $1.08 Billion Expected in 2016 - - Adjusted EPS of $2.10 - $2.20 Expected in 2016; GAAP EPS of $1.56 - $1.66 - - Conference Call and Webcast to Be Held At 10:00 a.m. EDT Today - LAKE FOREST, Ill., March 22, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today provided prelimina... 
Printer Friendly Version
03/07/16Akorn Receives Expected Additional Delinquency Notice From Nasdaq
Notice for Fourth Quarter and Full Year 2015 Expected Due to Ongoing Restatement Process LAKE FOREST, Ill., March 07, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX) today announced that, as expected, it has received a notice from the Nasdaq Listing Qualifications Staff stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company did not timely file its Form 10-K for the year ended December 31, 2015 with the Securities and Exchange Commission (SEC) ... 
Printer Friendly Version
02/25/16Akorn Announces Conference Call to Provide Business Updates; Partial Prepayment of Term Loan Facility
LAKE FOREST, Ill., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, announced that it will provide a business update the morning of March 22, 2016. In its update, Akorn will provide preliminary 2015 financial information and will supply initial 2016 financial guidance along with other business updates. Conference Call and Webcast Details Akorn’s management will hold a conference call with interested investors and analysts at 1... 
Printer Friendly Version
01/27/16Akorn Announces Conclusion of Audit Committee Independent Investigation
LAKE FOREST, Ill., Jan. 27, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX) today announced that the Audit Committee of Akorn’s Board of Directors concluded its independent investigation into Akorn’s accounting and other matters. As previously disclosed, in April 2015, upon the recommendation of Akorn’s management and Board of Directors, the Audit Committee commenced an independent investigation concerning accounting errors involving transactions related to sales to wholesalers, direct p... 
Printer Friendly Version
01/21/16Akorn Appoints Greg Lawless as Chief Human Resources Officer
LAKE FOREST, Ill., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Gregory P. Lawless joined Akorn as Chief Human Resources Officer on January 18, 2016. Mr. Lawless joins Akorn from The Kraft Heinz Company, where he served most recently as Vice President, Human Resources over his 13 years at the company. In his most recent role at Kraft Heinz, Mr. Lawless was responsible for human resources needs for the c... 
Printer Friendly Version
01/19/16Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection
LAKE FOREST, Ill., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.5mg and 8mg/2mg strengths. This launch follows an October 15, 2015 Food and Drug Administration (FDA) approval for the product.  Additionally, Akorn recently launched Tobramycin Injection, USP 40 mg/mL in 2 mL and 30 mL multi-dose vials. This launch follows a September... 
Printer Friendly Version
01/14/16Akorn Provides Material Updates
- BDO USA, LLP Engaged as Independent Registered Public Accounting Firm - - Nasdaq Listing Extension Granted Through May 9, 2016 - - Conference Call Scheduled for 8:00 am ET on January 15, 2016 - LAKE FOREST, Ill., Jan. 14, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX) today announced that Akorn engaged BDO USA, LLP as the company’s independent registered public accounting firm and the company received a listing extension from Nasdaq through May 9, 2016. In addition, Akorn provided an... 
Printer Friendly Version